stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Net income
Denali Therapeutics Inc.'s net income for fiscal 2025 was −$512.5M, compared with −$422.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$314.4M. Over the past ten years it has ranged from −$512.5M (fiscal 2025) to $71.1M (fiscal 2020) — the current reading is the lowest in ten years. Denali Therapeutics Inc. ranks 563rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$512.5M | — |
| FY2024 | −$422.8M | — |
| FY2023 | −$145.2M | — |
| FY2022 | −$326.0M | — |
| FY2021 | −$290.6M | — |
| FY2020 | $71.1M | — |
| FY2019 | −$197.6M | — |
| FY2018 | −$36.2M | — |
| FY2017 | −$88.2M | — |
| FY2016 | −$86.7M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $70.1M | — |
| Jun 2026 | −$127.6M | — |
| Mar 2026 | −$128.4M | — |
| Dec 2025 | −$128.5M | — |
| 37 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $31.7M |
| ELVN Enliven Therapeutics, Inc. compare | −$105.9M |
| CELC Celcuity, Inc. compare | −$226.5M |
| DNLI Denali Therapeutics Inc. | −$314.4M |
| IDYA IDEAYA Biosciences, Inc. compare | −$420.0M |
| VRDN Viridian Therapeutics, Inc. compare | −$453.6M |
| DYN Dyne Therapeutics, Inc. compare | −$519.4M |
| VKTX Viking Therapeutics, Inc. compare | −$627.2M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$702.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on DNLI
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement